Drug company methodologies used for reporting in the UK pharmaceutical industry payment transparency database between 2015-2019: A content analysis
View ORCID ProfileJames Larkin, View ORCID ProfileBritta Matthes, Mohamed Azribi, Conor Kearns, View ORCID ProfileShai Mulinari, View ORCID ProfileEmily Rickard, View ORCID ProfileFrank Moriarty, View ORCID ProfileTom Fahey, View ORCID ProfilePiotr Ozieranski
doi: https://doi.org/10.1101/2024.04.12.24305382
James Larkin
1Department of General Practice, RCSI University of Medicine and Health Sciences, Dublin, Ireland
Britta Matthes
2Department for Health, University of Bath, Bath, UK
Mohamed Azribi
3School of Medicine, RCSI University of Medicine and Health Sciences, Dublin 2, Ireland
Conor Kearns
3School of Medicine, RCSI University of Medicine and Health Sciences, Dublin 2, Ireland
Shai Mulinari
4Department of Sociology, Lund University, Lund, Sweden
Emily Rickard
5Department of Social and Policy Sciences, Centre for the Analysis of Social Policy, University of Bath, Bath, UK
Frank Moriarty
6School of Pharmacy and Biomolecular Sciences, RCSI University of Medicine and Health Sciences, Dublin, Ireland
Tom Fahey
1Department of General Practice, RCSI University of Medicine and Health Sciences, Dublin, Ireland
Piotr Ozieranski
5Department of Social and Policy Sciences, Centre for the Analysis of Social Policy, University of Bath, Bath, UK

Data Availability
Data are available online at: Larkin, J. (2024). Disclosure UK Methodological Notes Data 2015, 2017, 2019 [Data set]. Zenodo.
Posted April 15, 2024.
Drug company methodologies used for reporting in the UK pharmaceutical industry payment transparency database between 2015-2019: A content analysis
James Larkin, Britta Matthes, Mohamed Azribi, Conor Kearns, Shai Mulinari, Emily Rickard, Frank Moriarty, Tom Fahey, Piotr Ozieranski
medRxiv 2024.04.12.24305382; doi: https://doi.org/10.1101/2024.04.12.24305382
Drug company methodologies used for reporting in the UK pharmaceutical industry payment transparency database between 2015-2019: A content analysis
James Larkin, Britta Matthes, Mohamed Azribi, Conor Kearns, Shai Mulinari, Emily Rickard, Frank Moriarty, Tom Fahey, Piotr Ozieranski
medRxiv 2024.04.12.24305382; doi: https://doi.org/10.1101/2024.04.12.24305382
Subject Area
Subject Areas
- Addiction Medicine (349)
- Allergy and Immunology (668)
- Allergy and Immunology (668)
- Anesthesia (181)
- Cardiovascular Medicine (2648)
- Dermatology (223)
- Emergency Medicine (399)
- Epidemiology (12228)
- Forensic Medicine (10)
- Gastroenterology (759)
- Genetic and Genomic Medicine (4103)
- Geriatric Medicine (387)
- Health Economics (680)
- Health Informatics (2657)
- Health Policy (1005)
- Hematology (363)
- HIV/AIDS (851)
- Medical Education (399)
- Medical Ethics (109)
- Nephrology (436)
- Neurology (3882)
- Nursing (209)
- Nutrition (577)
- Oncology (2030)
- Ophthalmology (585)
- Orthopedics (240)
- Otolaryngology (306)
- Pain Medicine (250)
- Palliative Medicine (75)
- Pathology (473)
- Pediatrics (1115)
- Primary Care Research (452)
- Public and Global Health (6527)
- Radiology and Imaging (1403)
- Respiratory Medicine (871)
- Rheumatology (409)
- Sports Medicine (342)
- Surgery (448)
- Toxicology (53)
- Transplantation (185)
- Urology (165)